Last update: July 31, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
An antibacterial quinolone used in the treatment of urinary tract infections.
Oral administration 4 times a day.
Its use is authorized in infants from 3 months of age (Sanofi 2008).
It is excreted in breastmilk in clinically insignificant amounts (Traeger 1980), much lower than the dose used in infants.
Hemolysis has been observed in a newborn whose breastfeeding mother was taking nalidixic acid (Chin 2001 --> Belton 1965).
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity or glucose-6-phosphate dehydrogenase deficiency (WHO 2002).
The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM